XCE853 / Lantern Pharma, Oregon Therap - LARVOL DELTA

Oregon Therapeutics and Lantern Pharma launch a strategic collaboration in the field of artificial intelligence to optimize the development of XCE853, a first-in-class drug candidate, a potent inhibitor… (Businesswire) - "Lantern Pharma...today announced an AI-enabled strategic collaboration with the biotechnology company company Oregon Therapeutics in order to optimize the development of its drug candidate XCE853...in new and targeted indications against cancer....Oregon Therapeutics is developing XCE853 in several oncology indications, including ovarian and pancreatic cancers, certain hematologic cancers, and several pediatric cancers, including neuro-oncology....'To date, our first metabolic inhibitor, XCE853, has demonstrated robust preclinical efficacy in in-vitro and in-vivo models of numerous cancer types,'...Our team looks forward to being able to efficiently select ideal development options and de-risk future clinical development decisions'....Under the terms of the collaboration, Lantern Pharma receives an equal share of intellectual property and drug development rights for newly discovered biomarkers...No further financial details regarding the collaboration have been disclosed."

Licensing / partnership • CNS Tumor • Hematological Malignancies • Oncology • Ovarian Cancer • Pancreatic Cancer